Islet transplantation with alemtuzumab induction and calcineurin-free maintenance immunosuppression results in improved short- and long-term outcomes

Transplantation

Volumn 86, Issue 12, 2008, Pages 1695-1701

  Froud, Tatiana ^a   Baidal, David A ^a   Faradji, Raquel ^a   Cure, Pablo ^a   Mineo, Davide ^a   Selvaggi, Gennaro ^a   Kenyon, Norma S ^a   Ricordi, Camillo ^a   Alejandro, Rodolfo ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Alemtuzumab; Calcineurin free; Graft survival and function; Islet transplantation

Indexed keywords

ALEMTUZUMAB; C PEPTIDE; DACLIZUMAB; DIPHENHYDRAMINE; ETANERCEPT; GRANULOCYTE COLONY STIMULATING FACTOR; HEPARIN; IMMUNOSUPPRESSIVE AGENT; INSULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARACETAMOL; PENTOXIFYLLINE; RAPAMYCIN; TACROLIMUS; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; CALCINEURIN; CANCER ANTIBODY; GLYCOSYLATED HEMOGLOBIN; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENGRAFTMENT; FOLLOW UP; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; ISLET TRANSPLANTATION; LEUKOPENIA; LONG TERM CARE; LYMPHOCYTE DEPLETION; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; OUTCOME ASSESSMENT; POSTOPERATIVE CARE; PRIORITY JOURNAL; RASH; SHORT COURSE THERAPY; SINGLE DRUG DOSE; TRANSPLANTATION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; BLOOD; BODY MASS; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; IMMUNOLOGY; METABOLISM; PANCREAS ISLET TRANSPLANTATION; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; BLOOD GLUCOSE; BODY MASS INDEX; C-PEPTIDE; CALCINEURIN; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOSUPPRESSIVE AGENTS; INSULIN; ISLETS OF LANGERHANS TRANSPLANTATION; SIROLIMUS; TACROLIMUS; TREATMENT OUTCOME;

EID: 58849101815     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31819025e5     Document Type: Article

References (29)

1. Ryan EA, Lakey JR, Paty BW, et al. Successful islet transplantation: Continued insulin reserve provides long-term glycemic control. Diabetes 2002; 51: 2148.
2. Ryan EA, Lakey JR, Rajotte RV, et al. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes 2001; 50: 710.
3. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230.
4. Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54: 2060.
5. Shapiro AM, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006; 355: 1318.
6. Redmon JB, Olson LK, Armstrong MB, et al. Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. J Clin Invest 1996; 98: 2786.
7. Strumph P, Kirsch D, Gooding W, et al. The effect of FK506 on glycemic responseasassessed bythe hyperglycemic clamp technique. Transplantation 1995; 60: 147.
8. Fernandez LA, Lehmann R, Luzi L, et al. The effects of maintenance doses of FK506 versus cyclosporin A on glucose and lipid metabolism after orthotopic liver transplantation. Transplantation 1999; 68: 1532.
9. Kasiske BL, Snyder JJ, Gilbertson D, etal. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178.
10. Navasa M, Bustamante J, Marroni C, et al. Diabetes mellitus after liver transplantation: Prevalence and predictive factors. J Hepatol 1996; 25: 64.
11. Scantlebury V, Shapiro R, Fung J, et al. New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients. Transplant Proc 1991; 23: 3169.
12. Senior PA, Zeman M, Paty B, et al. Changes in renal function after clinical islet transplantation: Four-year observational study. Am J Transplant 2007; 7: 91.
13. Weaver TA, Kirk AD. Alemtuzumab. Transplantation 2007; 84: 1545.
14. Huang E, Cho YW, Hayashi R, et al. Alemtuzumab induction in deceased donor kidney transplantation. Transplantation 2007; 84: 821.
15. Nishida S, Levi DM, Moon JI, et al. Intestinal transplantation with alemtuzumab (Campath-1H) induction for adult patients. Transplant Proc 2006; 38: 1747.
16. Thomas PG, Woodside KJ, Lappin JA, et al. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. Transplantation 2007; 83: 1509.
17. TzakisAG, KatoT, Nishida S, et al. Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation. Transplantation 2003; 75: 1512.
18. Noris M, Casiraghi F, Todeschini M, et al. Regulatory T cells and T cell depletion: Role of immunosuppressive drugs. J Am Soc Nephrol 2007; 18: 1007.
19. Watanabe T, Masuyama J, Sohma Y, et al. CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells. Clin Immunol 2006; 120: 247.
20. Walsh R, Ortiz J, Foster P, et al. Fungal and mycobacterial infections after Campath (alemtuzumab) induction for renal transplantation. Transpl Infect Dis 2008; 10: 236.
21. Froud T, Ricordi C, Baidal DA, et al. Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience. Am J Transplant 2005; 5: 2037.
22. Ricordi C, Lacy PE, Finke EH, et al. Automated method for isolation of human pancreatic islets. Diabetes 1988; 37: 413.
23. Ichii H, Pileggi A, Molano RD, et al. Rescue purification maximizes the use of human islet preparations for transplantation. Am J Transplant 2005; 5: 21.
24. Bennet W, Groth CG, Larsson R, et al. Isolated human islets trigger an instant blood mediated inflammatory reaction: Implications for intraportal islet transplantation as a treatment for patients with type 1 diabetes. Ups J Med Sci 2000; 105: 125.
25. Ozmen L, Ekdahl KN, Elgue G, et al. Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets: Possible application of the thrombin inhibitor melagatran in clinical islet transplantation. Diabetes 2002; 51: 1779.
26. Bloom DD, Chang Z, Fechner JH, et al. CD4+ CD25+ FOXP3+ regulatory T cells increase de novo in kidney transplant patients after im-munodepletion with Campath-1H. Am J Transplant 2008; 8: 793.
27. Lund T, FosbyB, Korsgren O, et al. Glucocorticoids reduce pro-inflammatory cytokines and tissue factor in vitro and improve function of transplanted human islets in vivo. Transpl Int 2008; 21: 669.
28. Zahr E, Molano RD, Pileggi A, et al. Rapamycin impairs in vivo proliferation of islet beta-cells. Transplantation 2007; 84: 1576.
29. Kaplan B, West P, Neeley H, et al. Use of low dose tacrolimus, mycophenolate mofetil and maintenance IL-2 receptor blockade in an islet transplant recipient. Clin Transplant 2008; 22: 250.